NDA 209355 · Bausch
Bryhali
Halobetasol Propionate · Topical
Last checked: Nov 20, 2026Latest source record: Nov 6, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Nov 6, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
28
6 Phase 3, 0 recruiting
FAERS reports
978
287 serious, 15 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 1, 2020.
BRYHALI ® (halobetasol propionate) lotion, 0.01% is indicated for the topical treatment of plaque psoriasis in adults. BRYHALI lotion is a corticosteroid indicated for the topical treatment of plaque psoriasis in adults. ( 1 )
Mechanism: Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- BRYHALI · HALOBETASOL PROPIONATE 0.01% · LOTION, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Halobetasol Propionate" as an intervention, any sponsor and status, largest first.
- Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque PsoriasisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT02462083 · 555 participants · Start Aug 11, 2015 · Primary completion Jan 31, 2017
Drug: IDP-118 Lotion · For: Plaque Psoriasis
Sites: Mobile, Alabama; Beverly Hills, California; Encinitas, California · 46 sites in all
Sun Pharmaceutical Industries, Inc.Industry
NCT05282771 · 402 participants · Start Apr 16, 2021 · Primary completion Feb 10, 2022
Drug: Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%; Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045% and 1 more · For: Plaque Psoriasis
Sites: Charlotte, North Carolina
- Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade HemorrhoidsPivotal-lookingCompleted
Citius Pharmaceuticals, Inc.Industry
NCT05348200 · 304 participants · Start Apr 22, 2022 · Primary completion Apr 20, 2023
Drug: Monad 1; Monad 2 and 3 more · For: Hemorrhoids
Sites: Huntsville, Alabama; Tucson, Arizona; Chula Vista, California · 16 sites in all
- Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque PsoriasisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT02514577 · 217 participants · Start Nov 7, 2015 · Primary completion May 1, 2017
Drug: IDP-122 Lotion; IDP-122 Vehicle Lotion · For: Plaque Psoriasis
Sites: Hot Springs, Arkansas; Encinitas, California; Encino, California · 15 sites in all
- Safety and Efficacy of IDP-122 in Participants With Plaque PsoriasisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT02515097 · 213 participants · Start Nov 5, 2015 · Primary completion Mar 15, 2017
Drug: IDP-122 Lotion; IDP-122 Vehicle Lotion · For: Plaque Psoriasis
Sites: Santa Ana, California; Boynton Beach, Florida; Clearwater, Florida · 15 sites in all
- Safety and Efficacy of IDP 118 in the Treatment of Plaque PsoriasisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT02045277 · 212 participants · Start Feb 2014 · Primary completion Nov 2014
Drug: IDP-118 Lotion; IDP-118 Monad HP Lotion and 2 more · For: Plaque Psoriasis
Sites: Encino, California; San Diego, California; Santa Rosa, California · 18 sites in all
- Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque PsoriasisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT02785172 · 154 participants · Start Apr 2016 · Primary completion Dec 2016
Drug: IDP-118 Vehicle Lotion; IDP-118 Vehicle Cream and 2 more · For: Psoriasis
Sites: Fullerton, California; La Mesa, California; San Diego, California · 14 sites in all
- Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT02785185 · 150 participants · Start Jun 2016 · Primary completion Dec 2, 2016
Drug: IDP-122 Vehicle Lotion; IDP-122 Vehicle Cream and 2 more · For: Psoriasis
Sites: Rogers, Arkansas; Beverly Hills, California; Carlsbad, California · 13 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective199
- psoriasis139
- pruritus99
- product use in unapproved indication81
- rash70
- dermatitis atopic58
- pain53
- arthralgia51
- dry skin51
- skin exfoliation47
- fatigue45
- product dose omission issue45
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 3 |
| 2006 | 2 |
| 2010 | 3 |
| 2011 | 6 |
| 2012 | 9 |
| 2013 | 14 |
| 2014 | 11 |
| 2015 | 26 |
| 2016 | 36 |
| 2017 | 27 |
| 2018 | 31 |
| 2019 | 53 |
| 2020 | 70 |
| 2021 | 84 |
| 2022 | 146 |
| 2023 | 235 |
| 2024 | 82 |
| 2025 | 71 |
| 2026 | 69 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Bryhali (Halobetasol Propionate)
2024 spending
$101K
Beneficiaries
136
228 claims
Per beneficiary
$739
$5.24 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $353,712 |
| 2021 | $238,201 |
| 2022 | $198,289 |
| 2023 | $141,568 |
| 2024 | $100,541 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities.
Bhatia ND, Vlahovic TC, Green LG, et al. · J Drugs Dermatol 2019 · Clinical Trial, Phase III, Multicenter Study
- Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion With a Ceramide-Containing Moisturizer in Adults With Psoriasis.
Kircik L, Jacobson A · J Drugs Dermatol 2024 · Randomized Controlled Trial
- Once-Daily Halobetasol Propionate 0.01% Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants.
Desai SR, Glick B, Del Rosso JQ, et al. · J Drugs Dermatol 2021 · Clinical Trial, Phase III, Multicenter Study
- Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%-5% Affected Body Surface Area.
Tanghetti EA, Bhatia N, Drew S, et al. · J Drugs Dermatol 2021 · Clinical Trial, Phase III, Multicenter Study
- Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities.
Tyring S, Kircik LH, Yamauchi P, et al. · J Drugs Dermatol 2020 · Clinical Trial, Phase III, Multicenter Study
- Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
· J Drugs Dermatol 2019 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.